Journal of Clinical and Cellular Immunology
Open Access

Eric T Kimchi

Publications

• Research Article
  Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer
  Author(s): Xiaoqiang Qi, Samuel SK Lam, Dai Liu, Dae Young Kim, Lixin Ma, Lu Alleruzzo, Wei Chen, Tomas Hode, Carolyn J Henry, Jussuf Kaifi, Eric T Kimchi, Guangfu Li and Kevin F Staveley-O’Carroll Xiaoqiang Qi, Samuel SK Lam, Dai Liu, Dae Young Kim, Lixin Ma, Lu Alleruzzo, Wei Chen, Tomas Hode, Carolyn J Henry, Jussuf Kaifi, Eric T Kimchi, Guangfu Li and Kevin F Staveley-O’Carroll
  
  Manipulation of immune system toward the rejection of established cancers has become the standard of care in some patients. Here we propose the development of an in situ autologous cancer vaccine, inCVAX, for the treatment of hepatocellular cancer (HCC). inCVAX is based on the induction of local immunogenic cancer cell death combined with local dendritic cell stimulation by intratumoral injection of the immune-activator N-dihydro-galactochitosan (GC). In a first set of experiments, cellular and molecular studies were performed to investigate the effect of inCVAX on immune activation in a murine model of HCC that we previously developed. Once large tumors were formed in mice, the tumor is surgically exposed and a laser fiber was inserted into the center of an individual tumor mass. Using a 10 mm diffuser tip, laser irradiation of 1.5 W was applied to heat the tumor at differen.. View More»
  DOI: 10.4172/2155-9899.1000438

  Abstract PDF

Relevant Topics